GA
PCRX icon

Gagnon Advisors’s Pacira BioSciences PCRX Stock Holding History

Gagnon Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.83M Hold
352,637
– – 4.85% 10
2026
Q2 		$8.95M Hold
352,637
– – 5.69% 7
2026
Q1 		$7.97M Buy
352,637
+91,729
+35% +$2.04M 5.86% 8
2025
Q4 		$6.75M Buy
260,908
+47,506
+22% +$1.13M 4.29% 11
2025
Q3 		$5.5M Hold
213,402
– – 3.4% 14
2025
Q2 		$5.1M Buy
213,402
+80,012
+60% +$2.02M 3.43% 14
2025
Q1 		$3.31M Hold
133,390
– – 2.34% 19
2024
Q4 		$2.51M Hold
133,390
– – 1.61% 23
2024
Q3 		$2.01M Hold
133,390
– – 1.3% 24
2024
Q2 		$3.82M Hold
133,390
– – 2.91% 19
2024
Q1 		$3.9M Hold
133,390
– – 3.38% 15
2023
Q4 		$4.5M Sell
133,390
-46,941
-26% -$1.37M 3.93% 14
2023
Q3 		$5.53M Hold
180,331
– – 4.63% 10
2023
Q2 		$7.23M Hold
180,331
– – 4.84% 9
2023
Q1 		$7.36M Hold
180,331
– – 4.94% 7
2022
Q4 		$6.96M Hold
180,331
– – 4.7% 10
2022
Q3 		$9.6M Sell
180,331
-55,114
-23% -$3.06M 6.21% 3
2022
Q2 		$13.7M Sell
235,445
-15,695
-6% -$1.03M 8.31% 1
2022
Q1 		$19.2M Hold
251,140
– – 8.83% 1
2021
Q4 		$15.1M Buy
251,140
+10,998
+5% +$606K 6% 2
2021
Q3 		$13.4M Buy
240,142
+26,925
+13% +$1.55M 5.33% 5
2021
Q2 		$12.9M Buy
213,217
+19,357
+10% +$1.23M 4.92% 6
2021
Q1 		$13.6M Hold
193,860
– – 5.59% 4
2020
Q4 		$11.6M Hold
193,860
– – 5.21% 6
2020
Q3 		$11.7M Hold
193,860
– – 7.15% 3
2020
Q2 		$10.2M Hold
193,860
– – 7.32% 4
2020
Q1 		$6.5M Hold
193,860
– – 6.07% 4
2019
Q4 		$8.78M Hold
193,860
– – 4.92% 8
2019
Q3 		$7.38M Buy
193,860
+86,448
+80% +$3.45M 4.58% 7
2019
Q2 		$4.67M Buy
+107,412
New +$4.56M 2.67% 21

Other funds holding PCRX

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Gagnon Securities
Gagnon Securities New York $577M AUM 61.61% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bridge City Capital
Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Gagnon Advisors's PCRX Position: Q3 2026 in Review

Gagnon Advisors held its Pacira BioSciences (PCRX) position steady in Q3 2026 at 352,637 shares worth $8.83M. The position accounts for 4.85% of the portfolio, ranked #10.

Gagnon Advisors first reported a position in PCRX in Q2 2019 and has held it in 30 quarters since. The position peaked at $19.2M in Q1 2022. 107 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Gagnon Advisors held 352,637 shares of Pacira BioSciences worth $8.83M as of Q3 2026.
  • Gagnon Advisors left its Pacira BioSciences share count unchanged in Q3 2026.
  • Pacira BioSciences made up 4.85% of Gagnon Advisors's portfolio in Q3 2026, its #10 holding.
  • Gagnon Advisors first reported a position in Pacira BioSciences in Q2 2019 and has held it in 30 quarters since.
  • Gagnon Advisors's Pacira BioSciences position peaked at $19.2M in Q1 2022.
  • 107 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Gagnon Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.